Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8691275 | 0.91 | AR (0.35) | FABP4KIF11ESR1POLBALDH1A1 | |
| SCHEMBL7105084 | 0.81 | KIF11 (0.36) | KIF11ALDH1A1TSHRHSD11B1ACHE | |
| SCHEMBL5891289 | 0.81 | ALDH1A1 (0.32) | ALDH1A1TSHRLMNAMAPTHTT | |
| SCHEMBL6672493 | 0.81 | FABP4 (0.38) | FABP4KIF11L3MBTL1ESR1POLB | |
| SCHEMBL10768905 | 0.80 | KIF11 (0.35) | KIF11ALDH1A1TSHRHSD11B1NR1H2 | |
| SCHEMBL526140 | 0.80 | FABP4 (0.37) | FABP4KIF11L3MBTL1ESR1POLB | |
| SCHEMBL1369135 | 0.77 | KIF11 (0.39) | FABP4KIF11L3MBTL1ESR1POLB | |
| SCHEMBL4443952 | 0.76 | FABP4 (0.35) | FABP4KIF11L3MBTL1ESR1 | |
| SCHEMBL11782114 | 0.76 | — | — | |
| SCHEMBL15757626 | 0.75 | LMNA (0.34) | ALDH1A1LMNAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014085413-A1 | DISUBSTITUTED OXAZOLIDIN-2-ONES 5-HYDROXYTRYPTAMINE RECEPTOR 2B ACTIVITY MODULATORS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-06-05 | — | — | WO | disclosed |
| US-8026263-B2 | Methods for inhibiting neoproliferative changes in blood vessel walls | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-27 | — | — | US | disclosed |
| US-20090048270-A1 | Compounds, Methods And Devices for Inhibiting Neoproliferative Changes in Blood Vessel Walls | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-19 | — | — | US | disclosed |
| US-20070293554-A1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2007-12-20 | — | — | US | disclosed |
| US-7235577-B1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-26 | — | — | US | disclosed |
| US-6803375-B1 | IMMUNOMODULATION IN A MAMMALIAN PATIENT WITHOUT CAUSING SUBSTANTIAL INHIBITION OF CYTOCHROME P-450 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048270-A1 | Compounds, Methods And Devices for Inhibiting Neoproliferative Changes in Blood Vessel Walls | PGF, VEGFA, MKI67 | FABP4 4032/4885KIF11 2931/4885L3MBTL1 1422/4885 |
| US-20070293554-A1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | NFATC1, ORAI1, KCNMA1 | FABP4 2891/4885KIF11 4687/4885L3MBTL1 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.